Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy.

By W. Maisel, L. Stevenson. American Journal of Cardiology, 2003

973 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/f011307ca983104f816d527378d8ef9a789da065

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Dobromir Petkov Dobrev
2. Jason G. Andrade
3. P. Khairy
4. Stanley Nattel
5. G. Raskob
6. Aaron M. Wendelboe

Citations in the corpus

• Rhythm control versus rate control for atrial fibrillation and heart failure. (2008, neutral): “Other 14 (2) 10 (1) 0.39 Noncardiovascular 35 ( 5 ) 53 (8) 0.06”
• Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. (2005, neutral): “Mediterranean 94 69 (73) 39 (41) 44 (47) 11 (12) 2449 859 (35) 1336 (55) 78 (3) 176 (7) 529 (22) 539 (22) 577 (24) 759 (31) Cyprus 2 1 0 2 0 20 8 12 0 0 4 15 1 0 Egypt 3 3 3 0 0 133 28 91 2 12 22 30 14 60 Greece 10 10 1 7 2 323 51 261 7 4 79 105 57 70 Israel 7 1 6 1 0 59 22 32 0 5 25 12 16 5 Italy 3”
• The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. (2014, background): “toms, 10%–26% in New York Heart Association class II–III, and 40%–50% for New York Heart Association class IV).(25) HF is associated with a 4.”
• Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved vs. Reduced Ejection Fraction (2016, neutral): “HF HFpEF HFrEF AF N=759 N=309 N=360 N=1191 Age, years 78±10 79 ± 11 77 ± 10 75 ± 11 Women, n (%) 355 (47) 182 (59) 123 (34) 514 (43) Height, cm 164 ± 11 162 ± 11 166 ± 10 166 ± 11 Weight, kg 75 ± 18 75 ± 19 77 ± 17 77 ± 18 Body mass index, kg/m 2 28 ± 5 29 ± 6 28 ± 5 28 ± 5 Systolic blood pressure, ”
• Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial (2016, neutral): “Also, the prevalence of HF in patients with AF has been estimated at 42%.(8) The combination of HF and AF leads to”